Battistella Marisa, Walker Scott, Law Shirley, Lok Charmaine
University Health Network, Toronto, Ontario, Canada.
Hemodial Int. 2009 Jul;13(3):322-8. doi: 10.1111/j.1542-4758.2009.00368.x. Epub 2009 May 28.
Catheter-related bacteremia (CRB) is a major cause of morbidity and mortality especially among patients receiving hemodialysis (HD). Antibiotic lock therapy represents a promising technique in the treatment of CRB. Several studies have evaluated antibiotics in combination with heparin as an interdialytic locking solution as adjunctive therapy for CRB. The objective of this study was to evaluate the chemical stability of the vancomycin in 4% sodium citrate in HD catheters as an interdialytic lock. Vancomycin was prepared and diluted with sodium citrate 4% and stored in polyvinyl chloride syringes, 2 carbothane dialysis catheters (Hemostar) and 2 dual floating HD catheters (CardioMed). Syringes were stored at 4 degrees C or 23 degrees C and the catheters were stored in an incubator at 37 degrees C for 72 hours. Samples underwent daily chromatographic analysis and the luminal concentration of vancomycn was determined on study days 0, 1, and 3. When vancomycin is reconstituted with normal saline to achieve a concentration of 50 mg/mL, and then further diluted in 4% sodium citrate, to achieve concentrations of either 1 or 3 mg/mL, and then stored at 4 degrees C, room temperature, or 37 degrees C, solutions were observed to retain >92% of the initial concentration for the study period of 3 days. Based on the fastest degradation rate determined with 95% confidence interval, >90% is retained for 6.53 days. We conclude that vancomycin-4% citrate solutions stored in polyvinyl chloride syringes or HD catheters are not significantly affected by temperature or concentration within the 72 hours storage period. Therefore, these solutions can be anticipated to be suitable as a HD interdialytic antibiotic lock in standard HD catheters.
导管相关菌血症(CRB)是发病和死亡的主要原因,尤其是在接受血液透析(HD)的患者中。抗生素封管疗法是治疗CRB的一种有前景的技术。多项研究评估了抗生素与肝素联合作为透析间期封管溶液用于CRB的辅助治疗。本研究的目的是评估万古霉素在HD导管中4%柠檬酸钠溶液作为透析间期封管液时的化学稳定性。万古霉素用4%柠檬酸钠配制并稀释,储存在聚氯乙烯注射器、2根聚氨酯透析导管(Hemostar)和2根双腔漂浮HD导管(CardioMed)中。注射器储存在4℃或23℃,导管在37℃的培养箱中储存72小时。每天对样品进行色谱分析,并在研究第0、1和3天测定万古霉素的管腔浓度。当万古霉素用生理盐水复溶至浓度为50mg/mL,然后进一步用4%柠檬酸钠稀释至浓度为1或3mg/mL,然后储存在4℃、室温或37℃时,观察到溶液在3天的研究期内保持>92%的初始浓度。根据95%置信区间确定的最快降解率,>90%的浓度可保持6.53天。我们得出结论,储存在聚氯乙烯注射器或HD导管中的万古霉素-4%柠檬酸盐溶液在72小时储存期内不受温度或浓度的显著影响。因此,这些溶液有望适合作为标准HD导管的HD透析间期抗生素封管液。